Inactive Instrument

News Reunion Neuroscience

Equities

FTRP

CA76134G1037

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression	23-09-18	CI
Reunion Neuroscience Brief: Reunion and MPM BioImpact Complete Plan of Arrangement Effective Today, whereby MPM Acquired Reunion in an all-cash transaction valued at Near US$13.1 million	23-08-01	MT
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement	23-08-01	AQ
Reunion Neuroscience Inc.(NasdaqGS:REUN) dropped from NASDAQ Composite Index	23-08-01	CI
MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. in a going private transaction.	23-07-31	CI
REUNION NEUROSCIENCE OBTAINS FINAL COURT ORDER FOR PROPOSED PLAN OF ARRANGEMENT	23-07-17	AQ
Reunion Neuroscience Gets Ontario Court's Final Approval for Acquisition by MPM BioImpact	23-07-14	MT
Reunion Neuroscience Brief: Adds In "Assuming Remaining Conditions Precedent Are Satisfied Or Waived", Anticipates Closing of Arrangement Will Occur On Or About July 21, 2023	23-07-14	MT
Reunion Neuroscience Brief: Says Obtained Final Court Order for Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Deal Valued at Near US$13.1 Million	23-07-14	MT
Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement	23-07-14	AQ
Reunion Neuroscience Brief: Arrangement remains subject to receipt of a final order of the Ontario Superior Court of Justice (Commercial List); Expected to be completed on or around July 21, 2023	23-07-13	MT
Reunion Neuroscience Brief: Shareholders Approve Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Tansaction Valued at Near US$13.1 Million	23-07-13	MT
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement	23-07-13	AQ
Reunion Neuroscience : Annual Information Form For the Fiscal Year Ended March 31, 2023 - Form 6-K	23-07-07	PU
Reunion Reports Q4 Results; Shareholders to Get US$1.12 Cash Per Share From Arrangement Agreement with MPM BioImpact	23-06-29	MT
Reunion Neuroscience Brief: Adds It Presented "Encouraging" Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting	23-06-29	MT
Reunion Neuroscience Brief: Common Holders to Receive Consideration of US$1.12 Per Share in Cash from Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12	23-06-29	MT
Reunion Neuroscience Brief: Says incurred a net loss from continuing operations of $6.5 million or $0.56 per share and $38.1 million or $3.28 per share for the three and 12 month periods ended March 31, 2023	23-06-29	MT
Reunion Neuroscience Brief: Says Rcognized a net loss from discontinued operations of $10.4 million for the 12 month period ended March 31, 2023; Adds No such loss was incurred during the three month period ended March	23-06-29	MT
Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	23-06-29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Reunion Neuroscience

Equities

FTRP

CA76134G1037

Summary

Filters